{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Duration of Overall Response', 'The duration of overall response is measured from the time measurement criteria are first met for', 'CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is', 'objectively documented (taking as reference for progressive disease the smallest measurements', 'recorded on study). The duration of overall CR is measured from the time measurement criteria', 'are first met for CR until the first date that recurrent disease is objectively documented.', 'Regeneron Pharmaceuticals, Inc.', 'Page 117 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'APPENDIX 2. RECOMMENDED DOSE MODIFICATION OR DISCONTINUATION AND', 'SUPPORTIVE CARE GUIDELINES FOR SPECIFIC CEMIPLIMAB RELATED', 'ADVERSE EVENTS', 'Section 8.3 provides the dose level reductions.', 'Regeneron Pharmaceuticals, Inc.', 'Page 118 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Colitis Adverse Event Management', 'COLITIS', 'REGN2810 Dosing', 'Diagnostic', 'Action and Guidelines', 'CTCAE v4.03 Grade', 'Management', 'Considerations', 'For diarrhea, treat symptomatically (loperamide, oral', 'hydration, electrolyte substitution and ADA colitis', 'diet). Endoscopy is recommended if symptoms persist.', 'Grade 1', 'No change in REGN2810', 'Grade 1 diarrhea that persist for >1 week should be', 'dose', 'Bowel obstruction', 'treated with the addition of oral diphenoxylate', 'Colitis', 'hydrochloride and atropine sulfate four times daily and', 'All attempts should be', 'Colitis microscopic', 'budesonide 9 mg daily', 'made to rule out other', 'causes such as', 'GI consultation and endoscopy is recommended to', 'metastatic disease,', 'confirm or rule out colitis for grade 2 diarrhea that', 'bacterial or parasitic', 'persists >1 week or grade 1-2 diarrhea with rectal', 'infection, viral', 'bleeding (additional guidelines for the treatment of', 'gastroenteritis, or the', 'Grade 2', 'persistent colitis are provided below).', 'first manifestation of', 'Enterocolitis', 'Grade 2 diarrhea should be treated with the addition of', 'an inflammatory', 'hemorrhagic', 'Hold until <Grade 1.', 'oral diphenoxylate hydrochloride and atropine sulfate', 'bowel disease by', 'Gastrointestinal (GI)', 'perforation', 'four times daily and budesonide 9 mg daily.', 'examination for stool', 'Necrotizing colitis', 'Grade 2 diarrhea with diffuse ulceration and bleeding', 'leukocytes, stool', 'Diarrhea:', 'seen on endoscopy may require oral steroids with', 'cultures, and a', 'All patients who', 'prolonged taper and represent an increased risk for the', 'Clostridium difficile', 'experience', 'development of bowel perforation.', 'titer', 'diarrhea should be', 'advised', 'When symptoms improve to grade 1 or less, steroid', 'to drink liberal', 'taper should be started and continued over no less than', 'quantities of clear', '4 weeks.', 'fluids.', 'In patients with Grade 2 enterocolitis, REGN2810', 'If sufficient oral', 'should be withheld and anti-diarrheal treatment should', 'fluid intake is', 'not feasible,', 'be started. If symptoms are persistent for more than', 'fluid and', 'one week, systemic corticosteroids should be initiated', 'Electrolytes', '(e.g., 0.5 mg/kg/day of prednisone or equivalent).', 'should be', 'When symptoms improve to Grade 1 or less,', 'substituted via', 'IV infusion.', 'corticosteroid taper should be started and continued', 'over at least 1 month.', 'Regeneron Pharmaceuticals, Inc.', 'Page 119 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}